Seeking Alpha

Complete Genomics, Inc. (GNOM)

GNOM is defunct.
  • Mar. 12, 2013, 9:51 AM
    BGI-Shenzhen receives approval from China's State Administration of Foreign Exchange for the company's acquisition of Complete Genomics (GNOM +0.8%). The deal has now obtained all the necessary regulatory authorizations. (PR)
    | Comment!
  • Dec. 31, 2012, 1:25 PM
    Complete Genomics (GNOM +0.3%) says that it and BGI-Shenzhen obtained clearance from the Committee on Foreign Investment in the U.S. regarding itI's proposed acquisition of GNOM late Friday. In addition, BGI also extended its all cash offer to purchase all outstanding shares of GNOM until 12:00am ET on Monday, January 7, 2013. The Offer was previously set to expire at 12:00 am ET on Monday, December 31, 2012.
    | Comment!
  • Nov. 26, 2012, 12:09 PM
    Ilumina (ILMN -3.6%) slips today on a Baird dowgrade to Neutral. Baird says there are near-term M&A risks, specifically citing ILMN's own bid for Complete Genomics (GNOM +0.2%) while chatter resurfaces about Roche (RHHBY.OB) potentially trying to buy ILMN again after falling to reach a deal earlier this year.
    | Comment!
  • Nov. 26, 2012, 8:57 AM
    California Judge Elizabeth Laporte agrees to review an earlier decision to invalidate certain claims of an Illumina (ILMN) patent. The ruling is connected to a case in which the company has accused Complete Genomics (GNOM) - which Illumina is trying to buy - of breaching its IP.
    | Comment!
  • Nov. 21, 2012, 11:33 AM
    BGI-Shenzhen has again extended the deadline for its tender offer to acquire Complete Genomics (GNOM +1.6%), a move that comes in response to Illumina's (ILMN +0.8%) recently disclosed competing bid earlier this month that was rejected by the life sciences company. BGI's tender offer now expires on December 14.
    | Comment!
  • Nov. 21, 2012, 8:26 AM
    Complete Genomics (GNOM +2.3%) rejects Illumina's (ILMN) $114M bid despite the $3.30/share offer exceeding a $3.15 agreed proposal from China's BGI-Shenzhen. Illumina's bid is also not dependent on funding, nor is it subject to government approval as a foreign investment. Illumina "cannot comprehend" how GNOM "could rationally come to the conclusion" Illumina's offer is not superior. GNOM's shareholders may well agree.
    | Comment!
  • Nov. 16, 2012, 5:40 PM
    After-hours top gainers, as of 5:15 p.m.: GNOM +12.5%. GTAT +5.1%. SWFT +4.6%. KFY +4.5%. STRI +4.5%
    After-hours top losers: KWK -10.4%. REGN -9.7%. BPZ -9.4%. FLO -9.2%. NSM -8.7%.
    | Comment!
  • Nov. 13, 2012, 12:04 PM
    Shares of Complete Genomics (GNOM +3.3%) are up today on a report that it received an unsolicited $3.30 per share bid from "Party H" on November 5th. The offer follows an earlier tender offer from BGI-Shenzhen last month. Complete Genomics told Party H the bid didn't "constitute a superior proposal" and would likely not gain anti-trust clearance.
    | Comment!
  • Sep. 17, 2012, 9:10 AM
    Premarket gainers: IRIS +45%. GNOM +15%. ODP +10%. KTOS +9%. CPRX +9%. TSLA +8%. DVAX +7%. CTIC +6%.
    Losers: THLD -23%.
    | Comment!
  • Sep. 17, 2012, 6:38 AM
    Genomics firm BGI-Shenzhen plans to purchase Complete Genomics (GNOM) for $3.15 a share through a tender offer. The deal price marks a 54% premium over Friday's closing price for Complete Genomics. (PR)
    | 1 Comment
  • Jul. 12, 2012, 9:10 AM
    Premarket gainers: GNOM +10%. VHC +7%.
    Losers: SVU -36%. INFY -10%. IMGN -6%. NMFC -5%. PGR -5%.
    | Comment!
  • Jul. 12, 2012, 8:53 AM
    Complete Genomics (GNOM) +9.2% premarket and adding to a surge of 44% yesterday after it announced that its Long Fragment Read (LFR) technology, a new way of mapping DNA, "dramatically improves accuracy...and significantly reduces" the amount required for testing." That should make it more accessible to patients. (PR)
    | Comment!
  • Jun. 5, 2012, 3:33 PM
    Complete Genomics' (GNOM +5.3%) restructuring and postponement of capacity expansion are incremental positives for Illumina (ILMN +1.1%), observes Leerink Swann. The firm says v pricing in the whole human genome sequencing market could stabilize as a result of GNOM' actions.
    | Comment!
  • Jun. 5, 2012, 8:56 AM
    Complete Genomics (GNOM) +9.8% premarket after announcing it's laying off ~20% of its workforce to cut costs and has hired a financial adviser to help it explore strategic options including a possible sale of the company. GNOM says it is delaying expanding its monthly genome capacity until customer demand increases.
    | Comment!
  • May 25, 2012, 9:05 AM
    Premarket gainers: GNOM +20%. FRO +7%.
    Losers: DCTH -36%. TLB -27%. GENE -11%. PAY -10%. NYMT -6%. VRML -6%.
    | Comment!
  • May 8, 2012, 3:57 PM
    Complete Genomics (GNOM -16%) drops hard after missing on its Q1 late yesterday on wider-than-expected losses. Revenue was down 42% Y/Y, largely due to an unexpected revenue recognition deferral for 200 units previously sold into Q2.
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for GNOM.
Sector: Healthcare
Industry: Biotechnology
Country: United States